CMBA
AMRX icon

C.M. Bidwell & Associates’s Amneal Pharmaceuticals AMRX Stock Holding History

C.M. Bidwell & Associates’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65
Closed -$651 – 487
2025
Q3 		$651 Hold
65
– – ﹤0.01% 459
2025
Q2 		$526 Buy
+65
New +$490 ﹤0.01% 418
2020
Q3 		– Sell
-29,550
Closed -$141K – 453
2020
Q2 		$141K Buy
+29,550
New +$122K 0.13% 166

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

C.M. Bidwell & Associates's AMRX Position: Q4 2025 in Review

C.M. Bidwell & Associates sold out of Amneal Pharmaceuticals (AMRX) in Q4 2025, closing a stake of 65 shares — an estimated $651 sold.

C.M. Bidwell & Associates first reported a position in AMRX in Q2 2020 and held it in 3 quarters. The position peaked at $141K in Q2 2020. 277 funds tracked by Wall St. Rank hold AMRX as of Q4 2025.

  • C.M. Bidwell & Associates reported no remaining Amneal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 65 Amneal Pharmaceuticals shares in Q4 2025, an estimated $651.
  • C.M. Bidwell & Associates first reported a position in Amneal Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • C.M. Bidwell & Associates's Amneal Pharmaceuticals position peaked at $141K in Q2 2020.
  • 277 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2025, filed 13 Feb 2026.